Vanda Pharmaceuticals Croissance future

Future contrôle des critères 4/6

Vanda Pharmaceuticals devrait augmenter ses bénéfices et ses revenus de 86.9% et de 18.9% par an respectivement, tandis que le BPA devrait croître de croître de 88.1% par an.

Informations clés

86.9%

Taux de croissance des bénéfices

88.1%

Taux de croissance du BPA

Biotechs croissance des bénéfices	28.4%
Taux de croissance des recettes	18.9%
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Low
Dernière mise à jour	08 Nov 2024

Mises à jour récentes de la croissance future

Recent updates

Vanda's Struggles Persist Despite New Drug Launches And Takeover Bids

Sep 05

Vanda Pharmaceuticals: I Believe That The Bidding War Is Not Over

Aug 08

Vanda Pharmaceuticals: Undervalued With Promising Pipeline And Acquisition Interest

Jun 18

Vanda Pharmaceuticals: Fanapt Bipolar Win Doesn't Change Much

Apr 05

Vanda Pharmaceuticals' (NASDAQ:VNDA) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Feb 15

Vanda Pharmaceuticals' Portfolio Likely Has Upside From 2024 Approvals, Underpinned By Cash

Feb 13

Vanda Pharmaceuticals Inc.'s (NASDAQ:VNDA) Low P/S No Reason For Excitement

Feb 10

News Flash: One Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Analyst Has Been Trimming Their Revenue Forecasts

Nov 11

One Forecaster Is Now More Bearish On Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Than They Used To Be

May 12

Prévisions de croissance des bénéfices et des revenus

NasdaqGM:VNDA - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	314	4	145	229	3
12/31/2025	272	5	101	185	4
12/31/2024	198	-19	-55	44	4
9/30/2024	191	-16	-123	-18	N/A
6/30/2024	182	-11	-110	-5	N/A
3/31/2024	178	-5	-115	-11	N/A
12/31/2023	193	3	-88	13	N/A
9/30/2023	212	12	26	26	N/A
6/30/2023	238	15	40	41	N/A
3/31/2023	257	16	59	60	N/A
12/31/2022	254	6	31	32	N/A
9/30/2022	258	6	49	49	N/A
6/30/2022	263	11	45	46	N/A
3/31/2022	266	18	59	59	N/A
12/31/2021	269	33	64	64	N/A
9/30/2021	268	34	56	57	N/A
6/30/2021	259	32	55	57	N/A
3/31/2021	253	32	60	62	N/A
12/31/2020	248	23	50	52	N/A
9/30/2020	241	19	41	42	N/A
6/30/2020	241	114	38	39	N/A
3/31/2020	237	117	34	35	N/A
12/31/2019	227	116	45	46	N/A
9/30/2019	219	122	50	51	N/A
6/30/2019	209	28	53	54	N/A
3/31/2019	197	22	12	38	N/A
12/31/2018	193	25	5	30	N/A
9/30/2018	184	13	-7	18	N/A
6/30/2018	177	1	N/A	12	N/A
3/31/2018	171	-5	N/A	5	N/A
12/31/2017	165	-16	N/A	-2	N/A
9/30/2017	159	-14	N/A	-7	N/A
6/30/2017	156	-10	N/A	-8	N/A
3/31/2017	150	-13	N/A	-9	N/A
12/31/2016	146	-18	N/A	-8	N/A
9/30/2016	140	-32	N/A	-7	N/A
6/30/2016	129	-41	N/A	-13	N/A
3/31/2016	121	-42	N/A	2	N/A
12/31/2015	110	-40	N/A	12	N/A
9/30/2015	93	45	N/A	-1	N/A
6/30/2015	80	53	N/A	-3	N/A
3/31/2015	63	36	N/A	-52	N/A
12/31/2014	50	20	N/A	-82	N/A
9/30/2014	44	-57	N/A	-80	N/A
6/30/2014	37	-61	N/A	-83	N/A
3/31/2014	35	-43	N/A	-54	N/A
12/31/2013	34	-21	N/A	-40	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: VNDA devrait devenir rentable au cours des 3 prochaines années, ce qui est considéré comme une croissance plus rapide que le taux d'épargne ( 2.6% ).

Bénéfices vs marché: VNDA devrait devenir rentable au cours des 3 prochaines années, ce qui est considéré comme une croissance supérieure à la moyenne du marché.

Croissance élevée des bénéfices: VNDA devrait devenir rentable dans les 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de VNDA ( 18.9% par an) devrait croître plus rapidement que le marché US ( 9% par an).

Croissance élevée des revenus: Le chiffre d'affaires de VNDA ( 18.9% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de VNDA devrait être élevé dans 3 ans

Vanda Pharmaceuticals Croissance future

Future contrôle des critères 4/6

Informations clés

Mises à jour récentes de la croissance future

Vanda Pharmaceuticals Inc. Revises Revenue Guidance for the Full Year 2024

Vanda Pharmaceuticals Inc. Reinstates Financial Guidance for the Full Year 2024

Price target increased by 23% to US$5.21

Consensus EPS estimates fall from profit to US$0.06 loss, revenue upgraded

Consensus revenue estimates increase by 27%

Recent updates

Vanda Pharmaceuticals Inc. Revises Revenue Guidance for the Full Year 2024

Vanda Pharmaceuticals Inc. to Report Q3, 2024 Results on Nov 06, 2024

Cycle Pharmaceuticals Limited cancelled the acquisition of Vanda Pharmaceuticals Inc. (NasdaqGM:VNDA for approximately $490 million.

FDA Declines to Approve Vanda's Marketing Application for Tradipitant in Gastroparesis

Vanda's Struggles Persist Despite New Drug Launches And Takeover Bids

Vanda Pharmaceuticals: I Believe That The Bidding War Is Not Over

Vanda Pharmaceuticals Inc. Reinstates Financial Guidance for the Full Year 2024

Vanda Pharmaceuticals Inc. to Report Q2, 2024 Results on Jul 31, 2024

Vanda Pharmaceuticals Inc.(NasdaqGM:VNDA) dropped from Russell 2000 Value-Defensive Index

Future Pak, Ltd. cancelled the acquisition of Vanda Pharmaceuticals Inc. (NasdaqGM:VNDA) from The Vanguard Group, Inc., Renaissance Technologies LLC, BlackRock, Inc. (NYSE:BLK), Butler Hall Capital LLC, Shareholder Capital LLC and others.

Cycle Pharmaceuticals Limited cancelled the acquisition of Vanda Pharmaceuticals Inc. (NasdaqGM:VNDA).

Vanda Pharmaceuticals: Undervalued With Promising Pipeline And Acquisition Interest

Cycle Pharmaceuticals Limited made a proposal to acquire Vanda Pharmaceuticals Inc. (NasdaqGM:VNDA) for approximately $490 million.

Future Pak, Ltd. cancelled the acquisition of Vanda Pharmaceuticals Inc. (NasdaqGM:VNDA) from The Vanguard Group, Inc., Renaissance Technologies LLC, BlackRock, Inc. (NYSE:BLK), Butler Hall Capital LLC, Shareholder Capital LLC and others.

Vanda Pharmaceuticals Inc. Reports Positive Results from A Second Phase III Study of Tradipitant in Motion Sickness

First quarter 2024 earnings released: US$0.072 loss per share (vs US$0.057 profit in 1Q 2023)

Price target increased by 23% to US$5.21

Vanda Pharmaceuticals Inc. to Report Q1, 2024 Results on May 08, 2024

Future Pak, Ltd. submits a proposal to acquire Vanda Pharmaceuticals Inc. (NasdaqGM:VNDA) from The Vanguard Group, Inc., State Street Corporation (NYSE:STT), BlackRock, Inc. (NYSE:BLK), Dimensional Fund Advisors LP and others for approximately $450 million.

Future Pak, Ltd. submits a proposal to acquire Vanda Pharmaceuticals Inc. (NasdaqGM:VNDA) from The Vanguard Group, Inc., State Street Corporation (NYSE:STT), BlackRock, Inc. (NYSE:BLK), Dimensional Fund Advisors LP and others for approximately $450 million.

Consensus EPS estimates fall from profit to US$0.06 loss, revenue upgraded

Vanda Pharmaceuticals: Fanapt Bipolar Win Doesn't Change Much

New minor risk - Share price stability

Vanda Pharmaceuticals' Fanapt (Iloperidone) Receives U.S. FDA Approval for the Acute Treatment of Bipolar I Disorder

Insider recently sold US$73k worth of stock

Founder notifies of intention to sell stock

Vanda Pharmaceuticals Announces FDA Update for Supplemental NDA for HETLIOZ in the Treatment of Insomnia

Vanda Pharmaceuticals' (NASDAQ:VNDA) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Consensus revenue estimates increase by 27%

Vanda Pharmaceuticals' Portfolio Likely Has Upside From 2024 Approvals, Underpinned By Cash

Vanda Pharmaceuticals Inc.'s (NASDAQ:VNDA) Low P/S No Reason For Excitement

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ® in the Treatment of Insomnia

Vanda Pharmaceuticals Inc. to Report Q4, 2023 Results on Feb 07, 2024

Vanda Pharmaceuticals Inc. Announces U.S. Food and Drug Administration Approval for VTR-297 for the Treatment of Onychomycosis

Vanda Pharmaceuticals Inc. Receives FDA Approval to Proceed with Investigational New Drug VCA-894A, a Novel Antisense Oligonucleotide Candidate for the Treatment of Charcot-Marie-Tooth Disease, Type 2S

Now 21% undervalued after recent price drop

Vanda Pharmaceuticals Inc. Announces U.S. Food and Drug Administration Accepts New Drug Application for Tradipitant for the Treatment of Gastroparesis

Now 21% undervalued after recent price drop

News Flash: One Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Analyst Has Been Trimming Their Revenue Forecasts

Third quarter 2023 earnings released: EPS: US$0.002 (vs US$0.058 in 3Q 2022)

Vanda Pharmaceuticals Inc. to Report Q3, 2023 Results on Nov 08, 2023

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Vanda Pharmaceuticals Inc. to Report Q2, 2023 Results on Jul 27, 2023

Senior VP recently sold US$96k worth of stock

Senior VP notifies of intention to sell stock

Vanda Pharmaceuticals Inc Reports Results from a Phase III study of Tradipitant in Motion Sickness

One Forecaster Is Now More Bearish On Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Than They Used To Be

Vanda Pharmaceuticals Inc. Responds to the Ruling in its Hetlioz(R) Abbreviated New Drug Application Appeal

First quarter 2023 earnings released: EPS: US$0.057 (vs US$0.12 loss in 1Q 2022)

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance